Alcobra Ltd. (NASDAQ:ADHD) traded down 1.9% during mid-day trading on Thursday . The stock traded as low as $4.58 and last traded at $4.70, with a volume of 63,960 shares trading hands. The stock had previously closed at $4.79.

Several equities research analysts recently issued reports on the company. Canaccord Genuity assumed coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating on the stock. Roth Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Alcobra in a report on Tuesday, June 21st. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Thursday, April 28th. Finally, Cantor Fitzgerald assumed coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Alcobra presently has a consensus rating of “Buy” and a consensus target price of $10.63.

The company has a 50-day moving average of $4.80 and a 200-day moving average of $4.74. The company’s market capitalization is $133.95 million.

Alcobra (NASDAQ:ADHD) last announced its earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Equities analysts anticipate that Alcobra Ltd. will post ($0.98) earnings per share for the current fiscal year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.